Liver function tests: Their role in the diagnosis of hepatobiliary diseases

Journal of Infusion Nursing

Volumn 28, Issue 2, 2005, Pages 108-117

  Knight, Joseph A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ALANINE AMINOTRANSFERASE; ALBUMIN; ALCOHOL; ALKALINE PHOSPHATASE; ALPHA 1 ANTITRYPSIN; AMINOTRANSFERASE; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BROMSULFOPHTHALEIN; CHOLESTEROL; CYTOSOL AMINOPEPTIDASE; GAMMA GLUTAMYLTRANSFERASE; HEPARIN; HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN M; LACTATE DEHYDROGENASE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PREALBUMIN; TOXIN; UNINDEXED DRUG; VIRUS RNA;

ALCOHOL LIVER DISEASE; AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; DIFFERENTIAL DIAGNOSIS; ERYTHROCYTE LIFESPAN; HEMOCHROMATOSIS; HEPATOBILIARY DISEASE; HERB; HUMAN; HYPERBILIRUBINEMIA; LABORATORY TEST; LIVER BIOPSY; LIVER DISEASE; LIVER FUNCTION TEST; LIVER ISCHEMIA; LIVER NECROSIS; LIVER TOXICITY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; RISK FACTOR; SUBSTANCE ABUSE; VIRUS HEPATITIS;

EID: 15344340912     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129804-200503000-00004     Document Type: Review

References (44)

1. Arias E, MacDorman MF, Strobino DM, Guyer B. Annual summary of vital statistics-2002. Pediatrics. 2003;112:1215-1230.
2. Dufour DR. Detecting liver disease complications. Advance/Laboratory. 2003;February:58-63.
3. Pratt DS, Kaplan MM. Evaluation of abnormal liver enzyme results in asymptomatic patients. N Engl J Med. 2000;342:1266-1271.
4. Rej R. Measurement of aminotransferases: Part 1. Aspartate aminotransferase. CRC Crit Rev Clin Lab Sci. 1984;21:99-106.
5. Seeff LB, Cuccherini BA, Zimmerman H, et al. Acetaminophen hepatotoxicity in alcoholics. Ann Intern Med. 1986;104:399-404.
6. Ludwig J, Viggiano TR, McGill DB, Ott B. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438.
7. Byron D, Minuk GY. Profile of an urban hospital-based practice. Hepatology. 1996;24:813-815.
8. James O, Day C. Nonalcoholic steatohepatitis: another disease of affluence. Lancet. 1999;353:1634-1636.
9. Choi JW. Association between elevated serum hepatic enzyme activity and total body fat in obese humans. Ann Clin Lab Sci. 2003;33:257-263.
10. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988-1994. N Engl J Med. 1999;341:556-562.
11. Dufour DR, Lott JA, Nolte FS, et al. Diagnosis and monitoring of hepatic injury: II. recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem. 2000;46: 2050-2068.
12. Clermont RJ, Chalmers TC. The transaminase tests in liver disease. Medicine. 1967;46:197-207.
13. Gitlin N. The serum glutamic oxaloacetic transaminase/serum glutamic pyruvic transaminase ratio as a prognostic index in severe acute viral hepatitis. Am J Gastroenterol. 1982;77:2-4.
14. Giannini E, Botta E, Fasoli A, et al. Progressive liver functional impairment is associated with an increase in AST/ALT ratio. Dig Dis Sci. 1999;44:1249-1253.
15. Katkov WN, Friedman LS, Cody H, et al. Elevated serum alanine aminotransferase levels in blood donors: the contribution of hepatitis C virus. Ann Intern Med. 1991;115:882-884.
16. Renou C, Halfon P, Pol S, et al. Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels. Gut. 2000;51:585-590.
17. Gholson CF, Morgan K, Catinis G, et al. Chronic hepatitis C with normal aminotransferase levels: a clinical histologic study. Am J Gastroenterol. 1997;92:1788-1792.
18. Zylberberg H, Pol S, Thiers V, et al. Significance of repeatedly normal aminotransferase activities in HCV-infected patients. J Clin Gastroenterol. 1999;29:71-75.
19. Tarao K, Rino Y, Ohkawa S, et al. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer. 1999;86:589-595.
20. Whitehead MW, Hawkes ND, Hainsworth I, Kingham JGC. A prospective study of the causes of notably raised aspartate aminotransferase of liver origin. Gut. 1999;45:129-133.
21. Moseley RH. Evaluation of liver function tests. Med Clin North Am. 1996;80:887-906.
22. Ernst E. Harmless herbs? A review of the recent literature. Am J Med. 1998;104:170-178.
23. Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 1995;333:1118-1127.
24. Dickerman RD, Pertusi RM, Zachariah NY, et al. Anabolic steroid-induced hepatotoxicity: is it overstated? Clin J Sports Med. 1999;9:34-39.
25. Powell LW, George DK, McDonnell SM, Kowdley KV. Diagnosis of hemochromatosis. Ann Intern Med. 1998;129:925-931.
26. Krawitt EL. Autoimmune hepatitis. N Engl J Med. 1996;334: 897-903.
27. Kotal P, Vitek L, Fevery J. Fasting-related hyperbilirubinemia in rats: the effect of decreased intestinal motility. Gastroenterology. 1996;111:217-223.
28. Stein P, Rosalki SB, Foo AY, Hjelm M. Transient hyperphosphatasemia of infancy and early childhood: clinical and biochemical features of 21 cases and literature review. Clin Chem. 1987;33:313-318.
29. Tolaymat N, de Melo MC. Benign transient hyperphosphatasemia of infancy and childhood. South Med J. 2000;93:1162-1164.
30. Siraganian PA, Mulvihill JJ, Mulivor RA, Miller RW. Benign familial hyperphosphatasemia. JAMA. 1989;261:1310-1312.
31. Hoshino T, Kumasaka K, Kawano K, et al. A case of benign familial hyperphosphatasemia of intestinal origin. Clin Biochem. 1993;26:421-425.
32. Gordon T. Factors associated with serum alkaline phosphatase level. Arch Pathol Lab Med. 1993;117:187-190.
33. Wolf PL. Clinical significance of an increased or decreased serum alkaline phosphatase level. Arch Pathol Lab Med. 1978;102:497-501.
34. Knight JA, Haymond RE. Gamma-glutamyltransferase and alkaline phosphatase activities compared in serum of normal children and children with liver disease. Clin Chem. 1981;27:48-51.
35. Goldberg DM, Martin JV. Role of gamma-glutamyl transpeptidase activity in the diagnosis of hepatobiliary disease. Digestion. 1975;12:232-246.
36. Rosalki SB, Tarlow D, Rou D. Plasma gamma-glutamyl transpeptidase elevation in patients receiving enzyme-inducing drugs. Lancet. 1976;ii:376-377.
37. Moussavian SN, Becker RC, Piepmeyer JL, et al. Serum gamma-glutamyl transpeptidase and chronic alcoholism: influence of alcohol ingestion and liver disease. Dig Dis Sci. 1985;30:211-214.
38. Orrego H, Blake JE, Israel Y. Relationship between gamma-glutamyl transpeptidase and mean urinary alcohol levels in alcoholics while drinking and after alcohol withdrawal. Alcohol Clin Exp Res. 1985;9:10-13.
39. Bogrel A, d'Houtand A, Geuguen R, Siest G. Relations between reported alcohol consumption and certain biological variables in an unselected population. Clin Chem. 1979;25:1242-1246.
40. Whitehead TP, Clarke CA, Whitefield AGW. Biochemical and haematological markers of alcohol intake. Lancet. 1978;i:978-981.
41. Gibbs J, Call W, Henderson W, et al. Preoperative serum albumin level as a predictor of operative mortality and morbidity. Arch Surg. 1999;134:36-42.
42. Noskin GA, AMA Advisory Group on Prevention, Diagnosis, and Management of Viral Hepatitis. Prevention, diagnosis, and management of viral hepatitis: a guide for primary care physicians. Arch Fam Med. 1995;4:923-934.
43. Gholson CF, Morgan K, Catinis G, et al. Chronic hepatitis C with normal aminotransferase levels: a clinical histologic study. Am J Gastroenterol. 1997;92:1788-1792.
44. Sacher RA, Peters SM, Bryan JA. Testing for viral hepatitis: a practice parameter. Am J Clin Pathol. 2000;113:12-17.